{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:51:17Z","timestamp":1740167477077,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T00:00:00Z","timestamp":1715299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s40121-024-00981-8","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T11:01:56Z","timestamp":1715338916000},"page":"1379-1389","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Implementation of AZD7442 (Tixagevimab\/Cilgavimab) COVID-19 Pre-exposure Prophylaxis (PrEP) in the Largest Health Maintenance Organization in Israel: Real-world Uptake and Sociodemographic and Clinical Characteristics Across Immunocompromised Patient Groups"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3300-1769","authenticated-orcid":false,"given":"Samah","family":"Hayek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galit","family":"Shaham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Dagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Serby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadar","family":"Duskin-Bitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adva","family":"Yarden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e1tia","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Idit","family":"Livnat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabada","family":"Dube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvia","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudhir","family":"Venkatesan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ran D.","family":"Balicer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doron","family":"Netzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alon","family":"Peretz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,10]]},"reference":[{"key":"981_CR1","unstructured":"Johns Hopkins University & Medicine. COVID-19 DashBoard [Internet]. 2022. [cited January 12, 2022].  https:\/\/gisanddata.maps.arcgis.com\/apps\/dashboards\/bda7594740fd40299423467b48e9ecf6. Accessed 12 Apr 2024."},{"key":"981_CR2","unstructured":"Worldometer. COVID-19 coronavirus pandemic. [Internet]. 2022. [cited April 25, 2022]. https:\/\/www.worldometers.info\/coronavirus\/. Accessed 25 Apr 2022."},{"issue":"8","key":"981_CR3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727\u201333.","journal-title":"N Engl J Med"},{"issue":"9","key":"981_CR4","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/S1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022;22(9):1293\u2013302.","journal-title":"Lancet Infect Dis"},{"key":"981_CR5","unstructured":"World Health Organization. Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. [Internet]. 2023. [cited December 28, 2023]. https:\/\/www.who.int\/news\/item\/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic. Accessed 12 Apr 2024."},{"key":"981_CR6","unstructured":"World Health Organization. WHO COVID-19 dashboard. [Internet]. 2023 [cited June 1, 2023]. https:\/\/covid19.who.int\/. Accessed 12 Apr 2024."},{"key":"981_CR7","volume":"20","author":"T Bahremand","year":"2023","unstructured":"Bahremand T, Yao JA, Mill C, Piszczek J, Grant JM, Smolina K. COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. Lancet Reg Health Am. 2023;20: 100461.","journal-title":"Lancet Reg Health Am"},{"issue":"7821","key":"981_CR8","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","volume":"584","author":"EJ Williamson","year":"2020","unstructured":"Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430\u20136.","journal-title":"Nature"},{"key":"981_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101965","volume":"59","author":"S Shoham","year":"2023","unstructured":"Shoham S, Batista C, Amor YB, Ergonul O, Hassanain M, Hotez P, et al. Vaccines and therapeutics for immunocompromised patients with COVID-19. EClinicalMedicine. 2023;59: 101965.","journal-title":"EClinicalMedicine"},{"key":"981_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068632","volume":"376","author":"ARYB Lee","year":"2022","unstructured":"Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, et al. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ. 2022;376: e068632.","journal-title":"BMJ"},{"key":"981_CR11","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes new long-acting monoclonal antibodies for pre-exposure prevention of COVID-19 in certain individuals. [Internet]. 2021. [cited December 28, 2023]. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure. Accessed 12 Apr 2024."},{"issue":"23","key":"981_CR12","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1056\/NEJMoa2116620","volume":"386","author":"MJ Levin","year":"2022","unstructured":"Levin MJ, Ustianowski A, De Wit S, Launay O, Avila M, Templeton A, et al. Intramuscular AZD7442 (tixagevimab\u2013cilgavimab) for prevention of Covid-19. N Engl J Med. 2022;386(23):2188\u2013200.","journal-title":"N Engl J Med"},{"key":"981_CR13","unstructured":"AstraZeneca. Evusheld (formerly AZD7442) long-acting antibody combination authorised for emergency use in the US for pre-exposure prophylaxis (prevention) of COVID-19. [Internet]. 2021. [cited December 28, 2023]. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2021\/evusheld-long-acting-antibody-combination-authorised-for-emergency-use-in-the-us-for-pre-exposure-prophylaxis-prevention-of-covid-19.html#. Accessed 12 Apr 2024."},{"key":"981_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n3064","volume":"375","author":"Z Kmietowicz","year":"2021","unstructured":"Kmietowicz Z. Covid-19: monoclonal antibodies authorised in US as alternative to vaccines for certain groups. BMJ. 2021;375: n3064.","journal-title":"BMJ"},{"key":"981_CR15","unstructured":"Israeli Ministry of Health. The Ministry of Health has instructed the HMOs to vaccinated immunosuppressed individuals with AstraZeneca's Evusheld vaccine. [Internet]. 2022. [cited December 28, 2023]. https:\/\/www.gov.il\/en\/departments\/news\/15022022-02. Accessed 12 Apr 2024."},{"issue":"18","key":"981_CR16","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","volume":"386","author":"YM Bar-On","year":"2022","unstructured":"Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Amir O, Freedman L, et al. Protection by a fourth dose of BNT162b2 against Omicron in Israel. N Engl J Med. 2022;386(18):1712\u201320.","journal-title":"N Engl J Med"},{"key":"981_CR17","unstructured":"US Food and Drug Administration. FDA announces Evusheld is not currently authorized for emergency use in the U.S. [Internet]. 2023 [cited June 1, 2023]. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-announces-evusheld-not-currently-authorized-emergency-use-us. Accessed 12 Apr 2024."},{"issue":"12","key":"981_CR18","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","volume":"385","author":"N Barda","year":"2021","unstructured":"Barda N, Dagan N, Ben-Shlomo Y, Kepten E, Waxman J, Ohana R, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385(12):1078\u201390.","journal-title":"N Engl J Med"},{"issue":"15","key":"981_CR19","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","volume":"384","author":"N Dagan","year":"2021","unstructured":"Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412\u201323.","journal-title":"N Engl J Med"},{"issue":"6","key":"981_CR20","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/cid\/ciac855","volume":"76","author":"R Najjar-Debbiny","year":"2023","unstructured":"Najjar-Debbiny R, Gronich N, Weber G, Stein N, Saliba W. Effectiveness of Evusheld in immunocompromised patients: propensity score\u2013matched analysis. Clin Infect Dis. 2023;76(6):1067\u201373.","journal-title":"Clin Infect Dis"},{"key":"981_CR21","doi-asserted-by":"crossref","unstructured":"Kertes J, Shapiro Ben David S, Engel-Zohar N, Rosen K, Hemo B, Kantor A, et al. Association between AZD7442 (tixagevimab-cilgavimab) administration and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, hospitalization, and mortality. Clin Infect Dis. 2023;76(3):e126\u2013e32.","DOI":"10.1093\/cid\/ciac625"},{"issue":"7","key":"981_CR22","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1080\/21645515.2017.1297908","volume":"13","author":"K Muhsen","year":"2017","unstructured":"Muhsen K, Cohen D. Rotavirus vaccines in Israel: uptake and impact. Hum Vaccin Immunother. 2017;13(7):1722\u20137.","journal-title":"Hum Vaccin Immunother"},{"key":"981_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100234","volume":"12","author":"Y Gorelik","year":"2022","unstructured":"Gorelik Y, Anis E, Edelstein M. Inequalities in initiation of COVID19 vaccination by age and population group in Israel-December 2020-July 2021. Lancet Reg Health Eur. 2022;12: 100234.","journal-title":"Lancet Reg Health Eur"},{"key":"981_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100130","volume":"7","author":"K Muhsen","year":"2021","unstructured":"Muhsen K, Na\u2019aminh W, Lapidot Y, Goren S, Amir Y, Perlman S, et al. A nationwide analysis of population group differences in the COVID-19 epidemic in Israel, February 2020\u2013February 2021. Lancet Reg Health Eur. 2021;7: 100130.","journal-title":"Lancet Reg Health Eur"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00981-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-024-00981-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-024-00981-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T03:29:46Z","timestamp":1716780586000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-024-00981-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["981"],"URL":"https:\/\/doi.org\/10.1007\/s40121-024-00981-8","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"type":"print","value":"2193-8229"},{"type":"electronic","value":"2193-6382"}],"subject":[],"published":{"date-parts":[[2024,5,10]]},"assertion":[{"value":"6 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Samah Hayek, Galit Shaham, Noa Dagan, Danielle Serby, Hadar Duskin-Bitan, Ran D. Balicer, Doron Netzer and Alon Peretz are employees of Clalit Health Services. Joseph Levy was an employee of Clalit Health Services at the time of this study and manuscript development; Dr Levy\u2019s current affiliation is the Hebrew University of Jerusalem. Clalit Research Institute received funding from AstraZeneca to support execution of this study. Institutional grants to Clalit Research Institute from Pfizer outside the submitted work and unrelated to COVID-19, with no direct or indirect personal benefits. Adva Yarden, C\u00e1tia Ferreira, Idit Livnat, Sabada Dube, Sylvia Taylor and Sudhir Venkatesan are employees of, and hold or may hold stock in, AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study used de-identified patient data and was approved by the Clalit Health Services institutional review board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}